MAR 2 9 2007 WEETIFICATE OF MAILING

 Customer Number 24024

Maribushi'

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Cassady et al.)	Examiner: not yet assigned		
Serial No.:	10/599,930)	Art Unit: 1624		
Filed:	October 19, 2006)	Confirmation No.: 6717		
For: MAYTANSINOID ANALOGS AS ANTITUMOR AGENTS)	Attorney Docket No.: 22727.04427		

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B forms and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

FOREIGN LANGUAGE DOCUMENTS

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for
foreign language documents, Applicant encloses herewith a copy of a Communication
from a foreign patent office in a counterpart application citing such documents, together
with an English-language version of that portion of the Communication indicating the
degree of relevance found by the foreign patent office.

	Notice (which	diling date of the first Office Action on the merits, but before a Final Office Action, of Allowance, or an action that otherwise closes prosecution in the application lever is earlier). Accordingly, Applicant submits the fee required under 37 C.F.R. $V(p)$. The fee is being paid in the following manner:					
		A check is attached in the amount of \$180.00 as required under 37 § 1.17(p).					
		The patent office is hereby authorized to charge the amount of \$180.00 and any related fee to Deposit Account No. 030172 .					
	Office application submit	resent Information Disclosure Statement is being filed after the mailing of a final Action, Notice of Allowance or an action that otherwise closes prosecution in the ation, but on or before the payment of the issue fee. Accordingly, Applicant ts the following Statement under 37 C.F.R. § 1.97(e) along with the fee required 37 C.F.R. § 1.17(p).					
		Each item of information contained in this information disclosure statement was cited in a Communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.					
		No item of information contained in this information disclosure statement was cited in a Communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.					
		AND, the fee is being paid in the following manner:					
		A check is attached in the amount of \$ as required under 37 § 1.17(p).					
		The patent office is hereby authorized to charge the amount of \$ and any related fee to Deposit Account No. 030172 .					
	Charge any additional fees required by this paper or credit any overpayment to Deposit Account No. 03-0172, order number 22727/04427.						
		Respectfully submitted,					
Date: _	Merc	h 23, 2007 By: Mill a. Olsbardy					
		Michael A. Olshavsky, Reg. No. 58,605 Customer Number 24024 (216) 622-8533					

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PT TRADEALTH	Complete if Known			
PADE	Application Number	10/599,930		
INFORMATION DISCLOSURE	Filing Date	October 19, 2006		
STATEMENT BY APPLICANT	First Named Inventor	Cassady et al.		
(Use as many sheets as necessary)	Art Unit	1624		
(ose as many sneets as necessary)	Examiner Name	not yet assigned		
Sheet 1 of 1	Attorney Docket Number	22727/04427		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Kupchan, S.M. et al. "Maytansine, a Novel Arfrom Maytenus ovatus", J. Am. Chem. Soc. V			
			_		
Examiner	T		Date		

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.